Carlo Spezzapria

CEO, RTM BREDA

January 09, 2017

Could you describe the way in which the Aerospace industry impacted RTM Breda’s activities and your outlook for the future years?

RTM Breda is a testing laboratory that was founded in 1917 in Milan, with a long-standing tradition of testing and metallurgy. Since 2006, it is part of Forgital Group, which, in the last ten years, has invested substantial capital in the aerospace sector.

The laboratory has two sites in northern Italy and employs more than 100 people. We have a customer base both within Italy and internationally. We are one of the largest laboratories in Italy thanks to the growth in the aerospace industry, which today represents 20% of our business. We forecast that it will increase to 40% by 2020. We have invested to obtain several approvals and we are looking outside of Italy for international growth.

Could you outline the key services you offer across your aviation segment?

We carry out testing on materials following approvals and we have an engineering consultancy department performing finite element analysis and engineering services. Technical competence is only a starting point. Third party accreditation and customer approvals are strategic for this kind of business. Holding more than fifty Nadcap approved tests is a solid base for us, but we have also achieved approvals from GE Aviation (General Electric Aviation), Snecma (SAFRAN Group), Pratt&Whitney and Rolls Royce. It has taken several years to reach this target, along with investments in machinery and staff training. Approvals are the way to reach customers; I would say it is the best form of marketing.

In the last two years, we managed a global Creep PTP (Proficiency Testing Program) for GE; results were used by them in order to approve the laboratories worldwide. It was a sort of gold medal for us.

What are the advantages and challenges of being a member of the Lombardy Aerospace Cluster?

The Lombardy Cluster has given us visibility and allowed RTM Breda to be known as a test facility. However, I feel that there should be a next step forward: an Italian Cluster. There is too much of a regional mentality in Italy, slowing down possible growth. I am trying to develop customers outside Italy and I think that we all should work to give a stronger image of Italian Aerospace companies. The challenge is to unify many different regional clusters but I think that the business will drive them together naturally.

What kinds of trends are you observing in the international market and where are you seeing the larger investments coming from?

Eastern Europe is investing a lot in the aerospace field, and we have good opportunities in countries such as Poland, the Czech Republic and Turkey. The aerospace industry is very strong in both the UK and France but it is difficult to gain entrance. In the United States, you will see that there is a large amount of testing laboratories but at the same time, there is a huge demand for testing from the aerospace industry. It has good opportunities.

How are you looking to grow in the next three to five years?

We had a €11 million turnover in 2015 and the company is running well. We aim to achieve € 15 million in three to four years, mostly through testing in the aerospace but also with our materials & engineering services. We would like to expand in terms of organic growth, together with the outsourcing of services; the possibility of developing a laboratory within the customer’s organization. You have to be close to the customer to be in business.

Do you have a final message for our international readership?

RTM Breda has accepted the challenge of being a reference in materials science, from testing stages to engineering solutions. Aerospace applications are the market where we want to be. A European laboratory has to face and overcome the competition of strong US organizations. We are working and investing many resources to be the Italian player in the aerospace market.

INTERVIEWS MORE INTERVIEWS

ANIQ describe the impact of the Coronavirus on Mexico’s chemical industry and outlines the challenges of the year ahead.
InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer.
Amphos 21 helps Chile’s miners to cope with the dearth of water in a sustainable and efficient manner.
India’s Pharmexcil discusses developments in the country’s pharmaceuticals segment.

MACIG

GBR speaks to Leopold Mboli Fatran, Minister of Mines and Geology of Central African Republic concerning the challenges of developing the country’s resource industries.

SUBSCRIBE TO OUR NEWSLETTER